U.S. Markets closed

Dynavax Technologies Corporation (DVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.43-0.21 (-3.72%)
At close: 4:00PM EDT

5.45 +0.02 (0.37%)
After hours: 7:59PM EDT

Dynavax Technologies Corporation

2100 Powell Street
Suite 900
EmeryVille, CA 94608
United States
510 848 5100
http://www.dynavax.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees231

Key Executives

NameTitlePayExercisedYear Born
Mr. Ryan SpencerCEO & Director545.59kN/A1978
Mr. David F. NovackPres & COO697.27kN/A1962
Mr. Michael S. OstrachCFO, Chief Bus. Officer & Sr. VP662.54kN/A1952
Dr. Robert JanssenChief Medical Officer & Sr. VP of Clinical Devel., Medical and Regulatory Affairs666.13kN/A1954
Mr. Justin BurgessPrincipal Accounting Officer & ControllerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.

Corporate Governance

Dynavax Technologies Corporation’s ISS Governance QualityScore as of December 9, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.